Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | See "Remarks" | March 03, 2023 | March 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date March 03, 2023 · Filed March 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 46,011 |
Last balance in matching sequence
After 2023-03-05 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-03-04 · Exercise / conversion · Acquired 20,107 · Balance 40,301 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 2 · 2023-03-05 · Exercise / conversion · Acquired 5,710 · Balance 46,011 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 59,760 |
Reported balance
After 2023-03-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-03 · Grant · Acquired 59,760 · Balance 59,760 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on March 3, 2023, with 14,940 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 60,321 |
Reported balance
After 2023-03-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-04 · Exercise / conversion · Disposed 20,107 · Balance 60,321 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4: Restricted share units were granted on March 4, 2022, with 20,107 vested on March 4, 2023, and 20,107 vesting on each of March 4, 2024, March 4, 2025, and March 4, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 11,422 |
Reported balance
After 2023-03-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-05 · Exercise / conversion · Disposed 5,710 · Balance 11,422 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5: Restricted share units were granted on March 5, 2021, with 5,710 vested on each of March 5, 2022 and March 5, 2023, 5,710 vesting on March 5, 2024, and 5,712 vesting on March 5, 2025. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on March 3, 2023, with 14,940 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027.
F4: Restricted share units were granted on March 4, 2022, with 20,107 vested on March 4, 2023, and 20,107 vesting on each of March 4, 2024, March 4, 2025, and March 4, 2026.
F5: Restricted share units were granted on March 5, 2021, with 5,710 vested on each of March 5, 2022 and March 5, 2023, 5,710 vesting on March 5, 2024, and 5,712 vesting on March 5, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2023 Filed Mar 7, 2023 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016708 · doc4.xml · derivative · entry 5 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,422 Underlying: Ordinary Shares · 5,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 5,710 vested on each of March 5, 2022 and March 5, 2023, 5,710 vesting on March 5, 2024, and 5,712 vesting on March 5, 2025. F5 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 5,710 vested on each of March 5, 2022 and March 5, 2023, 5,710 vesting on March 5, 2024, and 5,712 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,710 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016708 · doc4.xml · nonDerivative · entry 2 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016708 · doc4.xml · derivative · entry 4 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,321 Underlying: Ordinary Shares · 20,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 20,107 vested on March 4, 2023, and 20,107 vesting on each of March 4, 2024, March 4, 2025, and March 4, 2026. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 20,107 vested on March 4, 2023, and 20,107 vesting on each of March 4, 2024, March 4, 2025, and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016708 · doc4.xml · nonDerivative · entry 1 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 59,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016708 · doc4.xml · derivative · entry 3 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,760 Underlying: Ordinary Shares · 59,760 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 14,940 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 14,940 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:35 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 4,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014438 · doc4.xml · derivative · entry 2 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,829 Underlying: Ordinary Shares · 4,828 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 4,828 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 4,829 vesting on February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 4,828 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 4,829 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:35 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 4,828 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014438 · doc4.xml · nonDerivative · entry 1 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017051 · doc4.xml · derivative · entry 3 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,132 Underlying: Ordinary Shares · 5,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 5,710 vesting on each of March 5, 2022, March 5, 2023 and March 5, 2024 and 5,712 vesting on March 5, 2025. F4 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 5,710 vesting on each of March 5, 2022, March 5, 2023 and March 5, 2024 and 5,712 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,710 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017051 · doc4.xml · nonDerivative · entry 1 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 80,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017051 · doc4.xml · derivative · entry 2 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,428 Underlying: Ordinary Shares · 80,428 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 20,107 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 20,107 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:48 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 4,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014470 · doc4.xml · derivative · entry 2 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,657 Underlying: Ordinary Shares · 4,828 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 4,828 having vested on each of February 28, 2021 and February 28, 2022, 4,828 vesting on February 28, 2023 and 4,829 vesting on February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 4,828 having vested on each of February 28, 2021 and February 28, 2022, 4,828 vesting on February 28, 2023 and 4,829 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:48 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 4,828 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-014470 · doc4.xml · nonDerivative · entry 1 Inbar Galia · CIK 0001878086 · See "Remarks" 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.